`TOTAL PROMOTIONAL EXPENDITURES
`U.S. PERCENTAGE OF SALES BY PRODUCT, INCLUDING GENERICS
`Q4 2012 – Q3 2014
`
`2012
`
`Q4
`
`Q1
`
`Q2
`
`Q3
`
`Q4
`
`Q1
`
`2013
`
`2014
`
`Q2
`
`Q3
`
`Total
`
`Ixempra®
`Kadcyla®
`Perjeta®
`Tykerb®
`Xeloda®
`
`
`
`Total
`
`
`
`1.4%
`N/A
`2.5%
`1.3%
`0.1%
`
`0.6%
`
`
`
`0.9%
`5.1%
`1.1%
`0.3%
`3.5%
`
`2.7%
`
`
`
`2.1%
`1.3%
`0.9%
`0.2%
`0.1%
`
`0.5%
`
`
`
`0.7%
`0.7%
`1.0%
`0.1%
`0.4%
`
`0.5%
`
`
`
`0.3%
`0.8%
`0.8%
`6.0%
`0.6%
`
`1.0%
`
`
`
`4.0%
`0.6%
`0.3%
`
`
`
`0.0%
`
`0.3%
`
`0.6%
`0.5%
`0.7%
`
`
`
`0.2%
`
`0.4%
`
`0.3%
`0.5%
`0.4%
`
`
`
`0.2%
`
`1.3%
`0.8%
`0.7%
`1.0%
`0.6%
`
`0.7%
`
`Notes & Sources:
`¹ Excludes Herceptin®.
`Kadcyla® is indicated as a single agent for the treatment of people with HER2-positive metastatic breast cancer who have received prior treatment with Herceptin® and a taxane
`chemotherapy. See, e.g., Exhibit 2317. In contrast:
`Xeloda® can be used to treat colon, rectal, and other cancers. See, e.g., Exhibit 2246.
`Perjeta® received FDA approval for neoadjuvant breast cancer therapy. See, e.g., Exhibit 2211.
`Tykerb® is used to treat breast cancer, but is prescribed with a second medicine (Xeloda® or Femara®). See, e.g., Exhibit 2342.
`(These assertions and sources can be found in the report.)
`Includes brand and generic values.
`Ixempra® includes brand IXEMPRA 10/2007 BM0, identified in field 'Product.'
`Kadcyla® includes brand KADCYLA 02/2013 GTC, identified in field 'Product.'
`Perjeta® includes brand PERJETA 06/2012 GTC, identified in field 'Product.'
`Tykerb® includes brand TYKERB 03/2007 GSK, identified in field 'Product.'
`Xeloda® includes brand XELODA 05/1998 GTC, identified in field 'Product,' and generic capecitabine, identified in field 'Combined Molecule.'
`Includes Xeloda® (capecitabine), which is indicated for use with Tykerb® (lapatinib) in second-line therapy. Excludes other chemotherapeutic agents that may be used to treat breast
`cancer (e.g., vinorelbine), which are indicated for the use of other cancers. See Exhibit 2218 and Exhibit 2343.
`Calculated as promotional spend divided by sales at ex-manufacturer price.
`Products identified from Exhibit 2103 and Exhibit 2224.
`Data from IMS Health.
`
`IMMUNOGEN 2320, pg. 1
`Phigenix v. Immunogen
`IPR2014-00676
`
`